BULLETIN V2026-0956
NERVGEN PHARMA CORP. ("NGEN")
BULLETIN TYPE: Prospectus-Share Offering, Delist
BULLETIN DATE: March 13, 2026
TSX Venture Tier 2 Company
Prospectus-Share Offering :
Financing Type: At-the-market Prospectus Offering
Gross Proceeds: $1,519.27 in the quarter ended March 4, 2026
Offering: 245 Listed Shares
Offering Price: An average price of $6.20 per Listed Share
Commissions in Securities: N/A
Disclosure: Refer to the prospectus supplement dated December 19, 2024, and the
Company's news releases dated July 8, 2025, and March 12, 2026.
Delist:
Further to the completion of the ATM Offering, effective at the close of business March 16, 2026, the common shares of NervGen Pharma Corp. will be delisted from TSX Venture Exchange at the request of the Company.
The Company will continue to trade on the Nasdaq Capital Market.
26/03/13 - TSX Venture Exchange Bulletins
TSX VENTURE COMPANIES
_______________________________________
|
|
